Was gehört zu Thrombozytenaggregationshemmer?
Zu den Thrombozytenaggregationshemmern zählen unter anderem:
- Acetylsalicylsäure.
- ADP-Rezeptorblocker (Blockade des P2Y12-Subtyps) Ticlopidin. Clopidogrel. Prasugrel. Ticagrelor.
- Glykoprotein-IIb/IIIa-Rezeptorantagonisten. Abciximab. Eptifibatid. Tirofiban.
Wann Antikoagulation und Thrombozytenaggregationshemmer?
Streng genommen besteht ein Unterschied zwischen den Wirkstoffen: Die Thrombozytenaggregationshemmer beeinflussen die Funktion der Blutplättchen; die Antikoagulantien wirken dagegen auf die Gerinnungsfaktoren des Blutes ein.
Wann welche Antikoagulation?
Eine prophylaktische Antikoagulation ist bei Erkrankungen und klinischen Situationen indiziert, bei denen ein erhöhtes Risiko für Thrombosen besteht, zum Beispiel bei: Herzklappenprothesen. Vorhofflimmern. Venenthrombose.
What is the mechanism of action of ADP inhibitors?
Mechanism of action. The molecular target of the active metabolite of ADP receptor inhibitors is the P2Y 12 receptor. P2Y 12 receptor is a G-coupled receptor and is activated by adenosine diphosphate. ADP binds to the P2Y 12 receptor that leads to inhibition of adenyl cyclase and thereby decreases the intracellular levels of cAMP.
Is clopidogrel an ADP inhibitor?
Adenosine Diphosphate Receptor Inhibitors ADP receptor inhibitors are small molecule inhibitors of the P2Y 12 ADP receptor, which include the following: clopidogrel (via PO, T 1/2 7–8 hours), prasugrel (via PO, T 1/2 7 [2–15] hours), ticlodipine (via PO, T 1/2 12 hours), and ticagrelor (via PO, T 1/2 7–8.5 hours).
What is adenosine diphosphate ADP?
Adenosine diphosphate (ADP) is a platelet agonist that is stored in platelet-dense granules. When a platelet is activated, ADP is released and binds to platelet surface receptors, thus recruiting additional platelets to form a platelet plug.
How do adadp inhibitors prevent platelet aggregation?
ADP receptor inhibitors such as clopidogrel (Plavix®) and ticlopidine (Ticlid®) prevent platelet aggregation by selectively and irreversibly binding the platelet surface receptor P2Y12. Platelet aggregation is inhibited for the remainder of the platelet lifespan (7–10 days).